IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by First Horizon Advisors Inc.

First Horizon Advisors Inc. boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 704 shares of the company’s stock after acquiring an additional 27 shares during the quarter. First Horizon Advisors Inc.’s holdings in IDEXX Laboratories were worth $356,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. American Century Companies Inc. grew its holdings in IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock valued at $274,179,000 after purchasing an additional 177,226 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after buying an additional 527,460 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in IDEXX Laboratories by 13.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company’s stock valued at $249,855,000 after buying an additional 59,519 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of IDEXX Laboratories by 12.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 390,565 shares of the company’s stock valued at $190,283,000 after acquiring an additional 43,473 shares in the last quarter. Finally, Clearbridge Investments LLC increased its position in shares of IDEXX Laboratories by 696.0% during the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company’s stock worth $171,891,000 after acquiring an additional 308,493 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.3 %

NASDAQ IDXX opened at $417.24 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The company has a 50-day simple moving average of $460.86 and a 200-day simple moving average of $480.70. The firm has a market capitalization of $34.17 billion, a PE ratio of 40.24, a price-to-earnings-growth ratio of 3.63 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. The company had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. IDEXX Laboratories’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.53 earnings per share. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on IDXX. Barclays reduced their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Piper Sandler restated a “neutral” rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $552.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.